This information does not constitute an offer, or an invitation to purchase, securities of Abu Dhabi Developmental Holding Company PJSC (ADQ) in the United States or in any other jurisdiction in which such offer or invitation is not authorised or to any person to whom it is unlawful to make such offer or solicitation.  Potential users of this information are requested to inform themselves about and to observe any such restrictions.ADQ's securities cannot be offered, sold, transferred or otherwise disposed of, in the United States, or to, or for the account or benefit of, U.S. persons (as defined in Regulation S under the Securities Act of 1933, as amended (the Securities Act)), absent registration, or an exemption from, or in a transaction not subject to, the registration requirements under the Securities Act.  ADQ has not registered, and does not intend to register, any of its securities under the Securities Act or to conduct a public offering of securities in the United States.This communication has not been approved by the United Kingdom Financial Conduct Authority. This communication does not constitute an offer of the securities to the public in the United Kingdom. This communication is being distributed to and is directed only at (i) persons who are outside the United Kingdom or (ii) persons who are investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the Order), and (iii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order, and (iv) any other persons to whom it may otherwise lawfully be communicated or caused to be communicated (all such persons in (i) to (iv) together being referred to as Relevant Persons). Any investment activity to which this communication relates will only be available to and will only be engaged with, Relevant Persons. Any person who is not a Relevant Person should not act or rely on this communication or any of its contents.This is an advertisement and not a prospectus for the purposes of Regulation (EU) 2017/1129 (the Prospectus Regulation). Investors should not subscribe for or purchase any securities referred to in this advertisement except on the basis of information contained in the base prospectus.

ADQ plans to bolster its healthcare and pharma portfolio by acquiring Amoun Pharmaceutical Company


  • ADQ to acquire Amoun, one of Egypt’s leading pharmaceutical and life sciences companies
  • The investment complements ADQ’s strategy to develop a fully integrated value chain in pharmaceuticals

ADQ, one of the region’s largest holding companies with a broad portfolio of major enterprises spanning key sectors of Abu Dhabi’s diversified economy, announced today that it has entered into a definitive agreement to acquire Amoun Pharmaceutical Company S.A.E. (Amoun), one of Egypt’s leading manufacturers, distributors and exporters of branded pharmaceutical and animal health products, from Bausch Health Companies Inc. (Bausch Health).

Amoun has a long-standing reputation for robust pharmaceuticals and life sciences products, addressing a wide range of acute and chronic conditions and highly prevalent diseases that demand treatment with proven high-quality medications. The company’s flagship products include Hibiotic, Antinal, Alphintern, and Neuroton. Amoun has more than 2,500 employees and owns one of the largest, state-of-the-art pharma plants in Egypt.

ADQ aims to develop an integrated healthcare and pharma value chain through strategic investments and new ventures both locally and internationally. Together with our recent pharma manufacturing investments in the UAE and India, our investment in Amoun will further enhance our pharma strategy with the ultimate aim of ensuring access to critical medicines, lowering the cost of medication for the general population and advancing new and innovative treatments that help improve people’s lives. Amoun’s extensive expertise in pharma and life sciences will provide ADQ with access to high demand pharmaceutical products, accelerating knowledge and technology transfer to enhance our local pharma manufacturing capacities.

Fahad Al Qassim, Executive Director, Healthcare & Pharma, at ADQ

Since our inception more than 20 years ago, Amoun has emerged as one of the largest, most well-known pharmaceutical companies in Egypt. Today, we are leaders in manufacturing, marketing and distributing quality pharmaceutical products in more than 25 markets across the globe. We believe that the credibility we have earned over the years with local and regional stakeholders, combined with ADQ’s strong emphasis on sustainable value creation will prove to be a very compelling combination.

Dr Mohamed S. Roushdy, President of Amoun Pharmaceutical Company

Fahad Al Qassim added: “Investing in Amoun further solidifies our commitment to the joint investment platform we established with the Sovereign Fund of Egypt (SFE). Together with SFE, we will work with Amoun’s leadership to expand on the company’s proven track record and market position in the pharma landscape.”

The investment in Amoun further strengthens ADQ’s long-term healthcare and pharma strategy to deliver a fully integrated value chain in the UAE. Across ADQ’s healthcare and pharma portfolio, SEHA is leading healthcare provision efforts and the imminent expansion through Pure Health’s diversified services portfolio of hospital management, laboratory services and medical supplies, to extend its reach across the emirates. In addition, ADQ’s recent acquisition of Pharmax locally, along with its investment in Biocon Biologics, will enable access to a wider range of generics and biosimilars, boosting local production capabilities and optimizing pharmaceutical expenditure.

The transaction will be completed through a mandatory tender offer (MTO) by ADQ for the total issued share capital of Amoun, including the less than 1 per cent held by minority shareholders. The transaction is subject to customary closing conditions, including regulatory approvals.

About ADQ

Established in 2018, ADQ is an Abu Dhabi-based investment and holding company with a broad portfolio of major enterprises. Its investments span key sectors of the UAE’s diversified economy including energy and utilities, food and agriculture, healthcare and life sciences, and mobility and logistics, amongst others. As a strategic partner of Abu Dhabi’s government, ADQ is committed to accelerating the transformation of the Emirate into a globally competitive and knowledge-based economy.

For more information, visit adq.ae or write to media@adq.ae. You can also follow ADQ on X, Instagram and LinkedIn.

Direct to your inbox

ADQ News and Insights delivered directly to your inbox

Latest News

The ADQ FWD platform brings together industry experts, government, and advocacy leaders to discuss and address issues of economic and strategic importance for the UAE.